(Reuters) -Drugmaker Merck said on Thursday that its pneumonia shot showed strong immune responses in children and teens who are at higher risk of serious illness, based on results from a late-stage study presented at a vaccines meeting in Lisbon.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed)

See Full Page